Evidence map›Paper›PMID 35434667›Full record

ArticleJTO clinical and research reports2022

De Novo

Meridith L Balbach, Rosana Eisenberg, Wade T Iams

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Clinically actionable molecular alterations in Rb-retained small cell lung carcinoma variants.Virchows Archiv : an international journal of pathology · 2026
    Article
  2. A favorable antitumor efficacy of sotorasib in a patient withInternational cancer conference journal · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meridith L BalbachDivision of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Rosana EisenbergVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Wade T IamsDivision of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Funding

Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
NCI NIH HHS K12 CA090625
6 · The paper itself

Abstract

The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously "undruggable" target. Here, we present the second reported case of de novo

Indexed as

Case reportKRAS G12CSmall cell lung cancerTargeted therapy

Identifiers

PMID35434667
PMCPMC9010630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.